Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and cx 4945

gefitinib has been researched along with cx 4945 in 4 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(cx 4945)		Trials
(cx 4945)		Recent Studies (post-2010) (cx 4945)
5,2315662,9191662162

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)cx 4945 (IC50)
Death-associated protein kinase 3Homo sapiens (human)0.017
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.056
Cyclin-dependent kinase 1Homo sapiens (human)0.056
Serine/threonine-protein kinase pim-1Homo sapiens (human)0.0465
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.056
Casein kinase II subunit alpha'Homo sapiens (human)0.1316
G1/S-specific cyclin-E1Homo sapiens (human)1.8
Cyclin-dependent kinase 2Homo sapiens (human)1.8
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0417
Casein kinase I isoform alphaHomo sapiens (human)0.004
Casein kinase I isoform deltaHomo sapiens (human)0.004
Casein kinase I isoform epsilonHomo sapiens (human)0.004
Dual specificity protein kinase CLK1Homo sapiens (human)0.012
Dual specificity protein kinase CLK2Homo sapiens (human)0.0039
Dual specificity protein kinase CLK3Homo sapiens (human)0.041
Casein kinase II subunit betaHomo sapiens (human)0.2833
Casein kinase II subunit alphaHomo sapiens (human)0.1968
Casein kinase I isoform gamma-2Homo sapiens (human)0.004
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)0.0069
Casein kinase II subunit alpha 3Homo sapiens (human)0.2516
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.056
Homeodomain-interacting protein kinase 3Homo sapiens (human)0.045
Dual specificity protein kinase CLK4Homo sapiens (human)0.011
Casein kinase I isoform gamma-1Homo sapiens (human)0.004
Serine/threonine-protein kinase pim-2Homo sapiens (human)0.186
Serine/threonine-protein kinase TBK1Homo sapiens (human)0.035
Dual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)0.0064

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Choi, CM; Choi, YJ; Chun, YJ; Kim, CH; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS; Song, JS1
Benveniste, EN; Dees, KJ; Gibson, SA; Hjelmeland, AB; McFarland, BC; Meares, GP; Nozell, SE; Rajbhandari, R; Rowse, AL1

Other Studies

4 other study(ies) available for gefitinib and cx 4945

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Apoptosis; Autophagy; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Naphthyridines; Phagosomes; Phenazines; Protein Kinase Inhibitors; Quinazolines

2014
Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
    Journal of neuro-oncology, 2017, Volume: 132, Issue:2

    Topics: AC133 Antigen; Animals; Brain Neoplasms; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Embryo, Mammalian; Enzyme Inhibitors; Female; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Naphthyridines; Neoplastic Stem Cells; Phenazines; Pregnancy; Quinazolines; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays

2017